
Morgan Stanley downgrades Novo Nordisk with $40 price target, citing earnings and revenue declines.
Morgan Stanley downgraded Novo Nordisk to "Underweight" with a price target of $40, implying a 9.11% downside from its recent price of $44.01. The downgrade reflects concerns over a projected 21.57% drop in earnings per share to $0.80 and a 2.35% rev...

